Copy
Problems viewing this newsletter? View it in your browser >



HIV Vaccine Awareness Day

May 5, 2015

Dear Advocate,

On Monday, May 18, advocates around the world will observe HIV Vaccine Awareness Day (HVAD)—an annual commemoration of the need for and commitment to the ongoing search for a vaccine. We invite you to join us on the day for a webinar—Vaccines in Vivo: Advances in AIDS Vaccine Research—at 10am US ET / 4pm South Africa / 5pm East Africa time (check www.timeanddate.com for your local time). We are also updating materials for vaccine advocates, including our “HVAD Toolkit” for those interested in easy-to-digest research updates. 

This year brought the launch of long-awaited initiation of clinical trials building on positive results from the RV144 “Thai” trial. This effort is led by the Pox-Protein Public-Private Partnership (P5), including the the HIV Vaccine Trials Network, who will join the webinar to provide a status update of their current vaccine research and development program. We will also feature Janssen, part of Johnson & Johnson, to provide an overview of the research program they are moving forward that focuses on a cross-clade vaccine product.

Join this webinar if you’d like to understand: 
  • When and where the P5 trials are taking place? 
  • What questions will be asked in the P5 “licensure track” trials—designed to bring a product to market, and what will the “research” track address? [Click here for AVAC’s explanation of the dual tracks.]
  • The pipeline beyond the P5 trials—including the candidate Janssen is developing
  • The role for advocates in southern Africa and around the world in terms of keeping AIDS vaccine research on track 
Click to register for the webinar.

This webinar will be the next installment in our Prevention on the Line series, a year-long dialogue on pressing issues in HIV prevention research and implementation. 

For advocates planning HVAD activities or simply looking for an update on the latest in the field, AVAC is updating its “HVAD Toolkit”, which includes a range of materials with HIV vaccine research highlights. The updated Toolkit will be available shortly at www.avac.org/hvad. Please email us if you're looking for a specific resource right away.

We look forward to commemorating another HVAD with all of you as we continue to work toward the ultimate goal of a vaccine to prevent HIV. AVAC would especially like to thank the Bill & Melinda Gates Foundation, International AIDS Vaccine Initiative, the US Agency for International Development, and our civil society partners in countries for supporting and partnering in HVAD and other vaccine advocacy initiatives.

We look forward to hearing your voices and questions in this discussion. And, as always, please email us at avac@avac.org with questions, comments and suggestions.

Best,
AVAC
 




Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 


Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 


Contact Us T: +1 212 796 6423
E: avac@avac.org

W: www.avac.org